Endocyte (ECYT) Stock Price, News & Analysis

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Key Stats

• Today's Range: $23.99 to $23.99
• 50-Day Range: N/A
• 52-Week Range: $2.81 to $24.00
• Volume: N/A
• Average Volume: 2.12 million shs
• Market Capitalization: $1.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ECYT Stock Analysis - Frequently Asked Questions

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.

What other stocks do shareholders of Endocyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Endocyte investors own include Bristol Myers Squibb (BMY), Meta Platforms (META), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), Netflix (NFLX) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/07/2018
• Today: 8/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ECYT
• CIK: 1235007
• Web: www.endocyte.com
• Phone: 765-463-7175
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.06 million
• Net Margins: -32,296.09%
• Pretax Margin: N/A
• Return on Equity: -21.19%
• Return on Assets: -20.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 45.80
• Quick Ratio: 45.80

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 28,133.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.99 per share
• Price / Book: 12.06

Miscellaneous

• Outstanding Shares: 82,090,000
• Free Float: N/A
• Market Cap: $1.97 billion
• Optionable: Optionable
• Beta: -0.01